Coherus Oncology (CHRS) Other Accumulated Expenses (2013 - 2026)

Coherus Oncology has reported Other Accumulated Expenses for 14 years, with the latest figure at $10.9 million in Q1 2026.

• Quarterly Other Accumulated Expenses fell 5.0% year-over-year to $10.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.9 million (down 5.0% YoY) and the FY2025 annual result came in at $11.3 million, down 43.81% from the prior year.
• Other Accumulated Expenses retreated to $10.9 million in Q1 2026 per CHRS's latest filing, from $11.3 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $20.0 million in Q4 2024 and troughed at $6.8 million in Q2 2025.
• A 5-year average of $12.0 million and a median of $11.4 million in 2025 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2025: Other Accumulated Expenses soared 204.52% in 2022, then sank 53.52% in 2025.
• Over 5 years, Other Accumulated Expenses stood at $10.6 million in 2022, then declined by 28.27% to $7.6 million in 2023, then jumped by 162.56% to $20.0 million in 2024, then plunged by 43.81% to $11.3 million in 2025, then retreated by 3.33% to $10.9 million in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $10.9 million, $11.3 million, and $7.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.